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9-(2-Phosphonyl-methoxyethyl)-adenine Promotes Erythrocytic 
Differentiation and Disrupts Cell Replication in Chronic Myelogenous 




Disruption during cellular differentiation can cause hematopoietic stem cells to proliferate 
uncontrollably, resulting in the development of cancer. Differentiation therapies are being 
investigated as a type of cancer treatment which involves inducing agents that promote the 
differentiation of cancer cells into those with similar properties to normal blood cells. These cells 
can then undergo apoptosis at an accelerated and controlled rate compared to cancer cells, 
making this a potential therapeutic technique. In this study, the ability of human chronic 
myelogenous leukemia K562 cells to undergo cellular differentiation in response to the inducing 
agent 9-(2-Phosphonyl-methoxy ethyl)-adenine (PMEA) is investigated. PMEA has previously 
been shown to disrupt cell replication and promote erythrocytic differentiation in K562 cells. In 
order to further test the effectiveness of this inducer, cell proliferation was measured with a cell 
growth curve, hemoglobin presence was measured with benzidine staining, and gamma-globin 
expression (a protein subunit of fetal hemoglobin) was measured in both induced and 
uninduced K562 cell cultures via RT-qPCR and western blotting. The results indicate that PMEA 
slows cell replication and promotes hemoglobin (and subsequently gamma-globin) expression in 
treated cells. In summary, the findings support the conclusion that PMEA is able to promote 
erythrocytic differentiation in K562 cells and provides information that supports differentiation 
therapies as a method for cancer treatment. 




Hematopoiesis occurs throughout both fetal development and adulthood and involves the 
formation of new blood cells from hematopoietic stem cells (HSCs) that are present in bone 
marrow (Jagannathan-Bogdan and Zon, 2013; Tsiftsoglou et al., 2003). These cells can 
differentiate according to various cellular pathways depending on the specific patterns of gene 
expression that occur, including either the myeloid or lymphoid pathways (Jagannathan-Bogdan 
and Zon, 2013; Andersson et al., 1979). The myeloid pathway can then further differentiate into 
other types of cells, such as red blood cells (erythrocytes). Erythrocytes express higher levels of 
hemoglobin and its constituent protein subunits compared to other hematopoietic progenitors, 
which can then be used as markers to measure cellular differentiation (Hatse et al., 1998; Hatse 
et al., 1999). 
If HSCs are disrupted during differentiation, it can lead to uncontrolled cellular 
proliferation and the development of cancer (Tsiftsoglou et al., 2003). Chronic myelogenous 
leukemia (CML) in particular, which is a type of leukemia present in adults and children, shows 
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a marked increase in the rate of cell division compared to normal HSCs, as a result of a 
translocation mutation between the 9th and 22nd chromosomes of these cells (Lozzio and 
Lozzio, 1975; Tsiftsoglou et al., 2003). This mutation causes the excision and joining of the bcr 
and c-abl genes from either chromosome and the expression of the tyrosine kinase oncoprotein 
Bcr-Abl. This oncoprotein stimulates uncontrolled cellular proliferation, which disrupts the 
normal rate of cell replication and leads to the development of cancer. K562 cells are a human 
CML cell line with similar properties to red blood cells which can be induced to differentiate into 
erythrocytic-like cells along the myeloid differentiation pathway (Hatse et al., 1998; Hatse et al., 
1999; Tsiftsoglou et al., 2003; Andersson et al., 1979). Erythrocytic differentiation causes these 
cells to express various types of hemoglobin that would not normally be expressed, such as 
HbF (fetal hemoglobin) (Tsiftsoglou et al., 2003). HbF contains alpha and gamma globin protein 
subunits, which can be used as specific markers of erythrocytic cellular differentiation (Chang et 
al., 2011; Hatse et al., 1998; Hatse et al., 1999; Tsiftsoglou et al., 2003). Since cancer cells are 
otherwise immortal, differentiation into erythrocytic-like cells slows the rate of tumor formation 
and cancer progression by increasing the rate of cell mortality (Tsiftsoglou et al., 2003). The 
current drug used to treat CML (imatinib mesylate) functions by specifically targeting and 
inhibiting tyrosine kinases such as the Bcr-Abl oncoprotein found in K562 cells. Though this 
drug has been effective as a therapeutic agent, multidrug resistance has become an issue since 
it reduces the effectiveness of this method of treatment. This makes finding inducing agents that 
can safely and reliably be used for differentiation therapies to induce cellular differentiation in 
cancer cells an important avenue to explore more in cancer research. This is especially 
important as a treatment option for CML which is otherwise commonly treated with methods that 
can be toxic, invasive, or cause side effects, such as chemotherapy, radiation, surgery, or stem 
cell transplants (Canadian Cancer Society, 2021). 
The objective of this project was to test the effectiveness of the inducing agent PMEA (9-
(2-Phosphonyl methoxyethyl)adenine) on cellular differentiation in the human K562 leukemia 
cell line. PMEA is known to influence the erythrocytic differentiation of K562 cells by promoting 
hemoglobin expression, particularly HbF, and by increasing the rate of cell death by stalling 
cellular replication (Hatse et al., 1998; and Hatse et al., 1999). The expression of the gamma-
globin protein subunit from HbF was measured as a marker of cellular differentiation to confirm 
whether or not PMEA was successful as an inducing agent on K562 cells (Tsiftsoglou et al., 
2003; and Salvador et al., 2013). In this study, we used a cell growth curve to measure cell 
proliferation, tested for hemoglobin expression via benzidine staining, and then looked 
specifically at gamma-globin expression via both RT-qPCR and Western Blotting procedures. It 
was predicted that because of PMEAs ability to induce HbF expression, those cells that were 
exposed to it should express gamma-globin more readily at both the level of RNA and protein, 
and thus undergo a higher rate of cellular differentiation into erythrocytic-like cells, compared to 
those K562 cells not exposed to PMEA (Hatse et al., 1998; Hatse et al., 1999). By measuring 
for the expression of gamma-globin after exposure to PMEA, we could further elaborate on the 
effectiveness of PMEA as an inducing agent on cellular differentiation and cell cycle arrest in 
K562 cells. However, this research will provide insight not only to the effect of PMEA as an 
inducing agent on K562 cells but will also provide relevant information about how inducing 
agents function in general to influence cancer cells, as well as why differentiation therapies 
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should be considered further in future cancer studies, or as an alternative method for CML 
cancer treatments. 
Materials and Methods 
Cell Culture and Harvesting 
Human CML K562 cell cultures were prepared according to an existing protocol (Hills et al., 
2020). A total of 1x105 K562 cells were suspended in 35mL of RPMI 1640 culture medium 
(Millipore Sigma) with either 500uL of PMEA solution added to the treated cultures (45mM final 
concentration) or 500uL of deionized water added to the untreated control cultures. Four PMEA 
treated and two untreated control cultures were prepared. After induction, the cells were 
cultured at 37℃ and 5% CO2 for 7 days. Passaging took place on day 3, and TC10 cell counts 
were taken daily using 10uL samples from a designated treated cell counting culture and a 
water control culture. This was done to measure the rate of cell proliferation and viability, where 
the data gathered was used to construct the growth curve seen in Fig 1. Following the culturing 
procedure 4x106 live cells from either treatment were harvested and stored at -20℃ for 
subsequent experiments.  
Benzidine Staining 
Prior to harvesting, 1mL of cell culture was taken from both the PMEA treated and the untreated 
samples to be used for staining. A benzidine stain containing 0.4% (10uL) of 35% H2O2 (v/v) to 
2.5mL of benzidine stock solution (0.2% w/v of benzidine dihydrochloride in 0.5M acetic acid) 
was prepared immediately prior to staining. A volume of 0.1mL of stain solution was added to 
each 1mL cell culture sample and then incubated for five minutes prior to counting. Cell counts 
were performed in triplicate using a hemocytometer, with 200-300 cells counted per replicate 
(Fig 2). 
RT-qPCR 
Total RNA was extracted from one treated and one untreated cell pellet sample, as outlined in 
the RNeasy ® Mini Kit (Qiagen). The purity and concentration of RNA obtained from the 
extraction was determined using a NanoPhotometer N60-Touch (Implen) which measured the 
concentration and the A260/A280 and A260/A230 ratios for both the treated and untreated cells (Tbl 
1). 
Denaturing gel electrophoresis was performed using the Formaldehyde-Free RNA Gel 
Kit (Amresco), a 2% agarose gel, and a 0.5-9kb RNA ladder. The gel was run at 5-8V/cm for 
~1.5-2 hours, and then the gel was imaged using the UVP BioSpectrum Multispectral imaging 
system using UV transillumination to confirm that the RNA was intact following extraction.  
Reverse transcription of RNA was performed using the QuantiTect Reverse 
Transcription Kit (Qiagen). A gDNA Wipeout Buffer (7x) was used to remove genomic DNA from 
the samples, and then the reverse transcription reaction proceeded according to protocol (Hills 
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et al., 2020), for a total of four reactions (one reaction with reverse transcriptase present and 
one without for each RNA sample).  
qPCR was performed on the obtained cDNA samples using a QuantiTect SYBR Green 
PCR Kit (Qiagen), along with the C1000 ThermoCycler with the CFX96 Real-Time System 
(BioRad). Six reactions were set up using the four cDNA samples: (1) Treated 18S rRNA control 
(2) Untreated 18S rRNA control (3) Treated ɣ-globin (4) Untreated ɣ-globin (5) Treated ɣ-globin
minus-RT control (6) Untreated ɣ-globin minus-RT control. 10X QuantiTect Primer Assays
(Qiagen) were used for amplification of the 18S cDNA and gamma-globin cDNA during qPCR:
(1) ɣ-Globin: Hs_HBG1_1_SG QuantiTect Primer Assay (200) - QT00041384 (2) 18S rRNA:
Hs_RRN18S_1_SG Quantitect Primer Assay (200) - QT00199367. Additionally, an 18S and
gamma cDNA control (no template added) were set up using the same reagents. The data
obtained was normalized using the 18S control values, and the relative fold change in gene
expression of gamma-globin was calculated using the 2(-ΔΔCt) method.
The qPCR products were run on a 2% agarose gel for 30-45 minutes at 100V according 
to protocol in Hills et al. (2020), then subsequently visualized using the UVP BioSpectrum 
Multispectral imaging system using UV transillumination to ensure that appropriate amplification 
took place. 
Western Blotting 
Total protein was isolated from one treated and one untreated pelleted K562 cell sample 
according to protocol (Hills et al., 2020). The cell pellets were washed and resuspended in 
500uL of ice-cold PBS, centrifuged at 4℃ and 1000RPM for 5 minutes, and then 250uL of lysis 
buffer (0.5% Triton X-100, 300mM NaCl, 50mM Tris-HCl (pH6.8) and 1mM PMSF) was added 
for 30 minutes, with regular vortexing to ensure full homogenization. The cells were then 
centrifuged again at 4℃ and 14,000 x g for 20 minutes before the supernatant was collected for 
further analysis. 
 Protein concentration was measured using a BioRad Protein Assay and compared to a 
BSA standard curve. Each concentration for the standard curve was prepared in triplicate, and 
the protein samples for the treated and untreated cells were prepared in duplicate. 250uL of dye 
solution and 5uL of each BSA standard or unknown protein sample was pipetted into each well 
on the microplate. The procedure was carried out according to protocol (Hills et al., 2020). The 
Beckman Coulter DTX 880 Multimode Detector was used to measure the absorbance (A595) of 
both the BSA standards and the treated/untreated K562 protein samples. 
Total protein samples of 20ug (15uL each) for both the treated and untreated protein 
samples were analyzed in triplicate using a 15% SDS-PAGE gel (+ 4% stacking gel) at 200V for 
30 minutes. Then a membrane transfer procedure was carried out according to protocol (Hills et 
al., 2020) to a PVDF membrane using the Bio-Rad PowerPac 200 at 100V for 1 hour. After the 
transfer, the membranes were stained using a Ponceau S stain solution for 10 minutes, and 
then visualized to ensure proper protein transfer had occurred (Fig 3A). 
A blocking procedure was carried out for 30 minutes using 10mL of a prepared buffer 
(20mM Tris, 500mM NaCl, pH 7.4, 1% w/v casein). The washing, antibody and staining 
procedures were performed according to protocol (Hills et al., 2020). The membrane was cut 
into three prior to antibody staining so that ɣ-globin as well as a 𝛼-globin and a GAPDH control 
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could be probed separately. Primary antibodies against ɣ-globin (1:200; mouse monoclonal, sc-
21757, Santa Cruz Biotech), 𝛼-globin (1:200; mouse monoclonal, sc-514378, Santa Cruz 
Biotech), and GAPDH (1:400; Cat. No. 68795, Sigma-Aldrich) were left on the membranes at 
4℃ for 48 hours before being washed with TBST and incubated with horseradish peroxidase 
(HRP) conjugated secondary antibodies (1:1000; goat anti-mouse IgG HRP conjugated, Bio-rad 
1705047) for 1 hour. Chromogenic detection was carried out using a CN/DAB substrate kit 
(ThermoFisher) until color developed (Fig 3B). The procedure was carried out according to 
protocol (Hills et al. 2020). 
Results  
Growth response of K562 cells to PMEA 
To understand how K562 proliferation is altered in response to PMEA, we monitored both cell 
concentration and viability from a designated treated counting culture and a water control 
(uninduced) culture (Fig 1). Following the one-week culturing procedure, the PMEA treated cell 
culture exhibited a lower concentration of both total and live cells than the untreated cell culture 
(Fig 1). The growth curve in Fig 1 shows a clear trend between the treated and untreated 
cultures, with the PMEA treated culture exhibiting lower total and live counts compared to the 
water control culture for every day that was measured. Following day 1 post induction, the 
treated and untreated cultures diverged in cell number more evidently as cultures were able to 
undergo more rounds of replication.  
Presence of hemoglobin in K562 cells 
Following the culturing procedure, cell samples were taken from both the treated and untreated 
cell cultures, and then exposed to a benzidine stain to test for the presence of hemoglobin. Cells 
were counted in triplicate for both samples with the average percent of blue stained cells 
(benzidine positive) recorded (Fig 2). According to the obtained data, the treated cell sample 
exhibited a much higher ratio of benzidine positive cells (454/898) than the control untreated cell 
sample (82/1168) (Fig 2). The data indicates that those cells that were exposed to PMEA before 
the 7-day incubation period expressed hemoglobin at a much higher concentration than those 
that were not exposed to PMEA. 
Gamma-Globin RNA expression 
In order to determine how PMEA influenced the expression of gamma-globin mRNA (our marker 
of differentiation), a series of experiments were performed to analyze the RNA from both the 
treated and the untreated cell cultures. Whole RNA was extracted from both cell samples, with 
those cells that were treated with PMEA exhibiting a lower concentration of total cellular RNA 
than the untreated cells (Tbl 1). The absorbance values obtained indicated that there was no 
protein/aromatic contamination in the samples (Wilfinger, 1997). Denaturing gel electrophoresis 
was performed on both samples, with two bands visualized (at 285 and 185bps) which 
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correspond to the total rRNA and mRNA present in either sample (data not pictured). The 
absence of a smear at the end of the gel indicated that our RNA samples were intact.  
A reverse transcriptase reaction was carried out, followed by qPCR with gamma-globin 
specific primers in order to measure the concentration of gamma-globin mRNA expressed in 
either cell sample (Tbl 2). Two rounds of qPCR were carried out, with the C(t) values normalized 
using an 18S RNA control. The qPCR products were run on an agarose gel, with bands of 
expected sizes for the samples with reverse transcriptase present (18S RNA and gamma-
globin), and no bands observed for the controls (no reverse transcriptase and gamma-
globin/18S cDNA primers with no template added) indicating no contamination (data not 
pictured). The relative fold increase in gene expression for gamma-globin in the PMEA treated 
samples following two rounds of qPCR was 11.70 and 11.88, indicating that gamma-globin was 
more heavily expressed in those cells treated with PMEA (Tbl 2). 
Gamma-globin protein expression 
To determine the effect of PMEA on K562 gamma-globin expression at the protein level, a 
series of experiments were performed to analyze the protein from both the treated and the 
untreated cell samples. Whole protein was extracted from both cell samples and quantified 
using a Bradford Assay and BSA standard curve (data not pictured). The protein extract from 
the treated cell samples had a concentration of 1.41x104ug/uL, and the untreated samples had 
a concentration of 1.34x104ug/uL.  
A western blot procedure was performed to test specifically for the presence of gamma-
globin protein expression. A Ponceau S staining procedure was performed to confirm successful 
electrotransfer of protein from the SDS-PAGE gel to the PVDF membrane (Fig 3A). Then, 
following antibody probing and chromogenic detection, bands for gamma-globin and for alpha-
globin and GAPDH controls were visualized (Fig 3B). For gamma-globin, and also surprisingly 
for alpha-globin, the treated samples exhibited higher expression of either protein compared to 
the untreated samples (Fig 3B). 
Figures and Tables 
Table 1. Quantification and absorbances of extracted whole cellular RNA from K562 treated and 
untreated cell lines 
Treated Untreated 
Concentration 0.9063ug/uL 1.1251ug/uL 
A260/A280 2.167 2.195 
A260/A230 2.016 2.260 
A260 22.70 28.19 
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Table 2. RT-qPCR C(t) values and relative fold change in gene expression for gamma-globin in PMEA 
treated and untreated K562 cell lines 
Round 1 C(t): 
Untreated 18S rRNA control (RT+): 12.12 
Treated 18S rRNA control (RT+): 12.61 
Untreated ɣ-globin (RT+): 15.06 
Treated  ɣ-globin (RT+): 12.00 
Untreated  ɣ-globin (RT- control): N/A (no contamination) 
Treated  ɣ-globin (RT- control): N/A (no contamination) 
Relative fold change in 
gene expression: 
11.70 
Round 2 C(t): 
Untreated 18S rRNA control (RT+): 13.31 
Treated 18S rRNA control (RT+): 16.3 
Untreated ɣ-globin (RT+): 15.17 
Treated  ɣ-globin (RT+): 14.59 
Untreated  ɣ-globin (RT- control): N/A (no contamination) 
Treated  ɣ-globin (RT- control): N/A (no contamination) 
Relative fold change in 
gene expression: 
11.88 
Figure 1. K562 cells treated with PMEA exhibit lowered rates of cellular proliferation. 
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Cell counts were taken daily with a TC10 cell counter, measuring the total number and live 
number of K562 cells from either a designated treated counting culture, or a water control 
sample (untreated). The PMEA treated cells exhibited lower total and live cell counts than the 
untreated cells for each day of incubation. Though there is a clear trend that PMEA treated 
samples proliferate at a slowed rate compared to the water samples, more samples would need 
to be taken per day before it could be determined if the increase in cell number was significantly 
different between the two treatments. 
 
Benzidine positive cells were counted in triplicate using a hemocytometer for both the treated 
and untreated K562 cell samples at one week post induction and shown in the figure above. 
The treated cells (n=3, x̄ = 49.93, SD: 5.4, CI(99%): 18.95-80.92%) exhibited significantly more 
benzidine positive cells than the untreated samples (n=3, x̄ : 7.03%, SD: 1.21, CI(99%) 
0.08-13.98) (p<0.01). 
Figure 2. PMEA treatment enhances hemoglobin expression in K562 cells
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(A) Ponceau staining of K562 whole cell protein extract samples (B) A western blot was probed  
with anti-Hbɣ, anti-Hb𝛼, and anti-GAPDH primary antibodies. Cells treated with PMEA exhibited 
increased globin expression compared to the untreated cells.
Discussion and Conclusions 
In previous studies, it has been shown that PMEA (9-(2-phosphonyl-methoxy ethyl)-adenine) 
influences human CML K562 cells to undergo cellular differentiation into homologues of 
erythrocytes and disrupts cell replication by halting the S-phase in cell replication (Hatse et al., 
1998; Hatse et al., 1999). In order to test the efficacy of PMEA, we performed a series of 
experiments on K562 cells to test for evidence of cell cycle disruption and erythrocytic 
differentiation by measuring the rate of cell replication and the expression of HbF and its 
constituent gamma-globin protein subunit in comparison to cells that were not exposed to 
PMEA. 
The growth curve generated during the 7-day incubation period supports the hypothesis 
that PMEA influences the ability of K562 cells to undergo replication, since cells treated with 
PMEA exhibited lower cell concentrations (for both live and total cells) for every day of the 
incubation period compared to those not treated with PMEA (Fig 1). These observations support 
the conclusion that PMEA disrupts S-phase in cell replication, which has been previously 
suggested in the available literature (Hatse et al., 1998; Hatse et al., 1999). However, the 
experiments performed did not specifically test for the specific phase of cell replication that was 
disrupted, and so although the results support previous findings, further experiments would 
need to be performed in order to confirm that it was S-phase that was disrupted during 
replication in our experiments. Additionally, although the results obtained show clear trends in 
Figure 3. K562 cells exposed to PMEA exhibit increased gamma and alpha globin expression  
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the rate of proliferation based on the growth curve obtained, more samples would need to be 
measured before we can confirm if the difference in number of cells between the two treatments 
was truly significant. 
Benzidine binds to hemoglobin (or heme groups) present in cells, allowing the benzidine 
stain procedure to act as a preliminary indicator of erythrocytic differentiation (Salvador et al., 
2013; Tfistsoglou et al., 2003). Since the cells treated with PMEA exhibited a much higher mean 
percent of benzidine positive cells than those not exposed to PMEA, it indicates that they 
expressed hemoglobin at an increased rate compared to the untreated cells (Fig 2) (Salvador et 
al., 2013).  This supports the conclusion that PMEA is involved in and promotes erythrocytic 
differentiation in K562 cells (Hatse et al., 1998; Hatse et al., 1999). Though the untreated 
samples did still exhibit some benzidine positive cells, this is most likely due to interactions 
between the benzidine stain and heme groups already present in these cells and is therefore 
not necessarily indicative of cellular differentiation (Fig 2).  
Following the RT-qPCR procedure, which was done to test for the expression of gamma-
globin at the level of mRNA, the PMEA treated cell samples exhibited an average relative fold 
increase in gamma-globin gene expression of 11.79 (Tbl 2). This indicated that the treated cells 
expressed gamma-globin mRNA to a much higher degree than those cells that weren’t exposed 
to PMEA. This was expected, since PMEA has been shown to induce hemoglobin (and thus 
gamma-globin) expression in previous experiments (Hatse et al., 1998; Hatse et al., 1999). 
Based on the clear trend seen between the two rounds of qPCR (Tbl 2), the results support the 
conclusion that PMEA promotes erythrocytic differentiation in K562 cells.  
The western blot procedure was done to further confirm how PMEA influences the 
expression of gamma-globin in K562 cells, since the RT-qPCR, benzidine stain, and growth 
curve procedures could not confirm the presence of gamma-globin at the protein level. Two 
western blot procedures were performed, with the PMEA treated samples exhibiting higher 
gamma-globin expression than the untreated samples in both. This further supports the 
conclusion that PMEA enhances erythrocytic differentiation in K562 cells (Hatse et al., 1998; 
Hatse et al., 1999). The GAPDH blot pictured in Fig 3B shows identical bands for both the 
untreated and treated K562 cell samples, but it is important to note that these controls, as with 
the alpha-globin controls, were probed separately from the gamma-globin samples (since the 
SDS-PAGE gel was loaded in triplicate, with each replicate subsequently probed with a 
separate primary antibody after the transfer procedure). Though the GAPDH control was probed 
separately from gamma-globin, the expression level was consistent between treatments and so 
it was still used (along with the results from the Ponceau S stain) to indicate consistent loading 
across samples. The results obtained from the alpha-globin blot show increased expression for 
the PMEA treated samples compared to the untreated samples, as was observed for gamma-
globin (Fig 3B). This was unexpected, since alpha-globin was intended as another control where 
consistent expression levels were anticipated between treatment groups. These results were 
consistent for both western procedures, elucidating as to the possibility that PMEA promotes 
globin expression in general, not just gamma-globin. Since it is anticipated that PMEA increases 
HbF expression, which contains both gamma and alpha globin subunits, this is a possibility 
(Tsiftsoglou et al., 2003). Further analysis would be required to determine if PMEA influences 
globin expression in general, but due to limitations on reagents and time, only gamma-globin 
expression was specifically measured in both the RT-qPCR and western procedures. However, 
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since the expression of alpha-globin was higher in the treated samples for both western 
procedures, and the benzidine stain revealed higher hemoglobin levels for the treated cells in 
general, this is a possible explanation.  
The overall results from the experiments performed support the conclusion that PMEA 
promotes erythrocytic differentiation in K562 cells and influences the rate of cell replication, as 
has been seen in previous studies (Hatse et al., 1998; Hatse et al., 1999). Further experiments 
would need to be conducted in order to measure the effect that PMEA has on the expression of 
other proteins, such as other hemoglobin subunits, during cellular differentiation. This would 
further aid in understanding the mechanisms that PMEA uses to promote cellular differentiation. 
It would also be beneficial to test the effect of PMEA on other types of cancer cells, or on 
normally functioning cells, to get a more holistic understanding of how PMEA disrupts and 
influences cellular processing. This would be necessary in order to measure any potential toxic 
or unexpected effects caused by exposure to PMEA before it could be used as an inducing 
agent for cancer treatments with humans. In conclusion, we have shown that PMEA promotes 
erythrocytic differentiation and cell cycle disruption in CML K562 cells. Therefore, PMEA has the 
potential to be a viable inducing agent that could be used for differentiation therapy as a form of 
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